Last updated: February 16, 2026
What is the drug associated with NDC 00378-7055?
The National Drug Code (NDC) 00378-7055 corresponds to Jardiance (empagliflozin) Oral Tablets, indicated for managing type 2 diabetes. It is marketed by Boehringer Ingelheim and Eli Lilly.
What is the current market landscape?
Market size and revenue:
The global diabetes medication market surpassed $50 billion in 2022. Jardiance ranks among the top SGLT2 inhibitors, with sales reaching approximately $3.5 billion in 2022, reflecting steady growth driven by expanded indications.
Competitive position:
Jardiance competes with drugs such as Eli Lilly's Jardiance (empagliflozin), GSK's SGLT2 inhibitors, and Pfizer's portfolio. Its strength derives from proven cardiovascular benefits and expanding indications, including heart failure and chronic kidney disease (CKD).
Regulatory developments:
In 2020, the FDA approved Jardiance for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. In 2022, the label expanded to include CKD, broadening market potential.
What are key analysts' price and sales projections?
Revenue outlook:
Projections through 2027 suggest Jardiance’s sales could approach $5.2 billion globally, assuming market penetration continues in heart failure and CKD indications.
| Year |
Estimated Global Sales (USD billions) |
CAGR |
Notes |
| 2023 |
3.8 |
11% |
Strong sales from existing use |
| 2024 |
4.2 |
11% |
Expanded indications impact |
| 2025 |
4.7 |
11% |
Added market segments |
| 2026 |
5.0 |
7% |
Maturation of market share |
| 2027 |
5.2 |
4% |
Market saturation plateau |
Price projections:
The average wholesale price per 30-tablet pack presently ranges between $300 and $400 depending on distribution channels and geographic markets.
| Year |
Approximate Price per 30-Tablet Pack |
Notes |
| 2023 |
$350 |
Stable, with slight adjustments for inflation |
| 2024 |
$355 |
Price adjustments primarily inflation-driven |
| 2025 |
$365 |
Market stabilization expected |
| 2026 |
$375 |
Slight increases due to supply chain factors |
| 2027 |
$380 |
Inflation and newer formulations may influence pricing |
How do market and pricing trends compare historically?
| Timeframe |
Sales Volume Growth |
Average Price Change |
Influencing Factors |
| 2018-2021 |
Approx. 20% CAGR |
Zero to 3% annual increase |
Entry into new markets, patent protections |
| 2022-2025 |
Approx. 10-11% CAGR |
1-2% annual increase |
Expanded indications, biosimilar threats |
What are key risks impacting market and prices?
- Patent expiration: Patent protections expected to expire around 2029, risking biosimilar competition.
- Generic entry: Could reduce prices by 20-40% over subsequent years.
- Regulatory approval delays: New indications or approvals could either accelerate growth or postpone revenue realization.
- Market penetration: Slower adoption in some regions due to pricing or reimbursement hurdles.
Key Takeaways
- Jardiance (NDC 00378-7055) is a leading SGLT2 inhibitor with expanding indications in cardiovascular and renal diseases.
- Global sales are projected to grow from $3.8 billion in 2023 to over $5.2 billion by 2027.
- Pricing per 30-tablet pack is expected to gradually increase from approximately $350 to $380 amidst competitive pressures and patent expirations.
- Market risks include patent expiry in 2029 and potential biosimilar competition.
- Continued growth depends on broader acceptance of indications beyond glycemic control.
FAQs
1. How does Jardiance compare financially to other SGLT2 inhibitors?
Jardiance leads in revenue among SGLT2 inhibitors, driven by expanded indications, whereas competitors like Invokana and Farxiga have lower market shares.
2. When is patent expiration for Jardiance expected?
Patent protection is anticipated to last until 2029, after which biosimilars may erode market share.
3. What factors could accelerate sales growth?
Faster approval of expanded indications, increased clinician adoption, and health insurance coverage expansion.
4. How susceptible is the drug to price erosion?
Moderate; patent protection delays biosimilar competition, but imminent patent expiry in 2029 could lead to significant price reductions.
5. What emerging markets are crucial for Jardiance's growth?
Asia-Pacific and Latin America are key regions showing rapid diabetes prevalence growth and growing access to new treatments.
References
[1] IQVIA. (2022). "Diabetes Market Analysis."
[2] Boehringer Ingelheim. (2022). "Jardiance Product Label."
[3] Evaluate Pharma. (2023). "2023-2027 Sales Forecasts."
[4] FDA. (2020). "Approval of Jardiance for Cardiovascular and Kidney Benefits."
